Is Sprycel a chemotherapy drug?

Q: Is Sprycel a chemotherapy drug?

Sprycel (dasatinib) is an oral targeted anticancer therapy classified as a tyrosine kinase inhibitor (TKI). It used to treat some types of blood cancer, such as Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (Ph+ CML) or acute lymphoblastic leukemia (Ph+ ALL).

Medically reviewed by Leigh Ann Anderson, PharmD. Last updated on Feb 3, 2025.

Official Answer by Drugs.com

Sprycel (dasatinib) is an oral anticancer targeted therapy classified as a BCR-ABL tyrosine kinase inhibitor (TKI) and is used to treat certain types of blood or bone marrow cancer. It is used in adults and children to treat Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (Ph+ CML) or acute lymphoblastic leukemia (Ph+ ALL) in various phases.

Sprycel is given as an oral tablet taken by mouth. You do not receive this medicine as an injection. For some patients, Sprycel may be used in addition to chemotherapy.

The Philadelphia chromosome is a defective string of DNA that promotes the production of leukemia cells. Leukemia most often refers to cancer of the white blood cells, which are needed to help the immune system fight off disease and infection. Leukemia is either acute (occurs quickly) or chronic (occurs over a longer period). Leukemia is not thought to be an inherited disease through families, but some forms may be diagnosed in close family members.

Specifically, Sprycel is approved by the FDA to treat:

adults with newly diagnosed Philadelphia chromosome–positive (Ph+) chronic myeloid leukemia (CML) in chronic phase
adults with Ph+ CML who no longer benefit from, or did not tolerate, other treatment, including imatinib mesylate (Gleevec)
adults with Ph+ acute lymphoblastic leukemia (Ph+ ALL) who no longer benefit from, or did not tolerate, other treatments
children 1 year of age and older with Ph+ CML in chronic phase
children 1 year of age and older with newly diagnosed Ph+ ALL in combination with chemotherapy

Which drugs are like Sprycel?

A list of BCR-ABL tyrosine kinase inhibitors includes:

imatinib (Gleevec): first approved in 2001; used to treat ALL, CML, myelodysplastic diseases, dermatofibrosarcoma protuberan (a rare type of skin cancer), cutaneous mastocytosis, gastrointestinal stromal tumor.
dasatinib (Sprycel): first approved in 2006; used to treat Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (Ph+ CML) or acute lymphoblastic leukemia (Ph+ ALL).
nilotinib (Tasigna): first approved in 2007; used to treat Ph+ CML or ALL
bosutinib (Bosulif) - first approved in 2012; used to treat Ph+ CML
ponatinib (Iclusig) - first approved in 2012; used to treat CML, Ph+ ALL

What are the most common side effects with Sprycel?

The most common side effects of Sprycel in adults and children receiving the medication as a single-agent therapy (occurring in at least 15% of patients) include:

low blood cell counts (bone marrow suppression) - can also be a serious side effect
fluid retention, swelling - can also be a serious side effect
diarrhea
headache
skin rash
hemorrhage (bleeding, blood loss) - can also be a serious side effect
shortness of breath (dyspnea)
fatigue
nausea
muscle and bone pain

Sprycel may also cause other serious side effects, such as:

heart problems
pulmonary arterial hypertension
severe skin reactions
tumor lysis syndrome

Important: See other side common and serious side effects related to Sprycel therapy. Talk to your doctor about these side effects, how to recognize them, and when to report them to a healthcare provider.

Does Sprycel cause hair loss (alopecia)?

Sprycel has been reported to cause hair loss (alopecia) in 1% to less than 10% of patients but is not listed as a common side effect. The manufacturer reported hair loss based on data gathered from 2,809 participants in pooled studies evaluating Sprycel use in chronic myeloid leukemia (CML) and adults in Ph+ ALL.

Sprycel may also rarely lead to changes in hair color (depigmentation). One case report in a 56 year old woman described depigmentation that began 2 months after Sprycel therapy was started for CML. Depigmentation worsened over 12 months, and was reversible 2 to 3 months after treatment was stopped. Hair loss was not specifically noted. Skin depigmentation on the face and trunk was also reported.

This is not all the information you need to know about Sprycel (dasatinib) for safe and effective use. Review the full Sprycel information here, and discuss this information and any questions you have with your doctor or other health care provider.

References

Sprycel (dasatinib) [product information]. Bristol Myers Squibb. Princeton, NJ. Updated 12/2018. Accessed Feb. 12, 2021 at https://packageinserts.bms.com/pi/pi_sprycel.pdf
Fujimi A, Ibata S, Kanisawa T, et al. Reversible skin and hair depigmentation during chemotherapy with dasatinib for chronic myeloid leukemia. Letter to the Editor. J Dermatol. 2016 Jan;43(1):106-7. doi:10.1111/1346-8138.13150. Epub 2015 Oct 5. PMID: 26434556.
Leukemia. Harvard Health. Drugs.com. Accessed Feb 14, 2021 at https://www.drugs.com/health-guide/leukemia.html

Which medications make you sleepy?

Many medications can make you sleepy – some intentionally – such as sleeping pills, but others can make you tired as a side effect or an unintended consequence of the medication. It is important to know before taking a medication if there is a chance it may make you sleepy, drowsy, tired, or fatigued, because this may have an impact on your driving or ability to operate machinery, and how competent you are to make good decisions. 13 common classes of medications can make you sleepy. Continue reading

Is small cell or non-small cell lung cancer worse?

Generally, small cell lung cancer (SCLC) is worse than non-small cell lung cancer (NSCLC). SCLC accounts for about 10-15% of people who have lung cancer and is the most aggressive form of lung cancer. SCLC usually starts in the breathing tubes (bronchi), and although the cells are small, they grow very quickly and create large tumors. Early on in the course of the disease, there are rarely any symptoms. If caught early (limited-stage disease) 20-25% of people can be potentially cured. Extensive SCLC is more difficult to treat. Continue reading

Is non-small cell lung cancer hereditary?

A hereditary family history of lung cancer is one of the many risk factors for developing non-small cell lung cancer. About 8% of lung cancers are thought to be inherited or linked to gene changes, but smoking and air pollution remain the primary causes of lung cancer. Continue reading

Is Sprycel a chemotherapy drug?

Which drugs are like Sprycel?

Related questions

What are the most common side effects with Sprycel?

Does Sprycel cause hair loss (alopecia)?

Read next

Which medications make you sleepy?

Is small cell or non-small cell lung cancer worse?

Is non-small cell lung cancer hereditary?

See also:

Aimovig

Nurtec ODT

Botox

Depakote

Topamax

Emgality

Timolol

Valproic acid

Divalproex sodium

Topiramate

Related medical questions

Drug information

Related support groups